ENDRA Life Sciences

NDRA · NASDAQ

$4.47−$0.28 (−5.89%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.75

NDRA analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $25.50 (+470.5% upside)

Low: $25.25
Now: $4.47
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

NDRA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Jun 1, 2026	Maintains	Buy	$27.00 → $25.00	28%
Ascendiant Capital	Dec 8, 2025	Maintains	Buy	$38.00 → $30.00	28%

The case for and against

Updated Mar 13, 2026

Bull case

ENDRA Life Sciences Inc. is developing the Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue in a manner similar to MRI, but at a lower cost and at the point of patient care. The anticipated FDA approval within the next year, underpinned by a favorable net present value (NPV) analysis, suggests substantial potential for the stock's appreciation. This innovative technology has the capacity to provide earlier diagnoses and more accurate monitoring of chronic liver conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing a significant unmet need in a market affecting over one billion individuals globally.

Bear case

ENDRA Life Sciences Inc. reported a net loss of $1.6 million in the latest quarter, resulting in an earnings per share (EPS) of $(2.10), which was worse than the previous estimate of $(1.95). The company also faced a recurring net loss of $1.2 million with an EPS of $(1.71), not aligning with the earlier expectations of $(2.27). The financial outlook is further challenged by various risks, including balance sheet and liquidity issues, potential failures in clinical trials or regulatory approvals, difficulties in commercialization and reimbursement, as well as competition and shifting macroeconomic conditions.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.